Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fidarestat SCHEMBL48827 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL1219758 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| Fidarestat SCHEMBL29546775 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL29941924 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL48828 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9250816 | 0.91 | AKR1B1 (0.83) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL8311471 | 0.91 | AKR1B1 (0.83) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL8311883 | 0.89 | AKR1B1 (0.81) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9411779 | 0.89 | AKR1B1 (0.80) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9411773 | 0.89 | AKR1B1 (0.80) | AKR1B1AKR1A1AKR1B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| EP-1778275-A2 | COMBINATION THERAPY FOR DIABETES, OBESITY, AND CARDIOVASCULAR DISEASES USING GDF-8 INHIBITORS | Wyeth (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020884-A2 | COMBINATION THERAPY FOR DIABETES, OBESITY, AND CARDIOVASCULAR DISEASES USING GDF-8 INHIBITORS | WYETH (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | WYETH | 2006-02-16 | — | — | US | claimed |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK SERONO SA (CH) | 2014-04-17 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | MERCK SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2002098510-A1 | COMBINATION OF A PTPASE INHIBITOR AND AN ALDOSE REDUCTASE INHIBITOR | WYETH (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20020161015-A1 | Ophthalmic composition | R-TECH UENO, LTD. | 2002-10-31 | — | — | US | disclosed |
| EP-1004307-B1 | OPHTHALMIC COMPOSITION | R TECH UENO LTD (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6403598-B1 | Ophthalmic composition | R-TECH UENO, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6339088-B1 | ADMINISTERING ALDOSE REDUCTASE INHIBITOR TO A SUBJECT IN NEED OF A TREATMENT OF EXOCRINE DISORDER EXCEPT HYPOLACRIMATION | R-TECH UENO. LTD. (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1161942-A2 | Ophthalmic composition | R-TECH UENO, LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
| EP-1004307-A2 | OPHTHALMIC COMPOSITION | R-Tech Ueno, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999038497-A2 | OPHTHALMIC COMPOSITION | R-TECH UENO, LTD. (JP) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034831-A1 | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors | DPP8, IGFBP1, IGFBP5 | AKR1B1 3076/4885AKR1A1 3587/4885AKR1B10 3385/4885 |
| US-20020161015-A1 | Ophthalmic composition | AKR1A1, AKR1C2, AKR1B1 | AKR1B1 3/4885AKR1A1 1/4885AKR1B10 7/4885 |
| US-20090029903-A1 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors | PTPRS, PTPRZ1, PTP4A1 | AKR1B1 128/4885AKR1A1 149/4885AKR1B10 330/4885 |
| US-20140107116-A1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | GPR119, GLS2, GLS | AKR1B1 764/4885AKR1A1 933/4885AKR1B10 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.